Australia markets close in 2 hours 24 minutes

Keymed Biosciences Inc. (2162.HK)

HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
37.550-0.500 (-1.31%)
As of 11:29AM HKT. Market open.
Currency in HKD

Valuation measures4

Market cap (intra-day) 10.52B
Enterprise value 8.04B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)26.01
Price/book (mrq)3.26
Enterprise value/revenue 21.03
Enterprise value/EBITDA -51.65

Trading information

Stock price history

Beta (5Y monthly) -0.08
52-week change 3-32.89%
S&P500 52-week change 326.36%
52-week high 364.800
52-week low 326.600
50-day moving average 334.289
200-day moving average 343.992

Share statistics

Avg vol (3-month) 31.53M
Avg vol (10-day) 31.5M
Shares outstanding 5276.6M
Implied shares outstanding 6292.05M
Float 8185.35M
% held by insiders 132.62%
% held by institutions 132.06%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in CNY.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -101.49%
Operating margin (ttm)-1,620.36%

Management effectiveness

Return on assets (ttm)-7.32%
Return on equity (ttm)-11.31%

Income statement

Revenue (ttm)354.1M
Revenue per share (ttm)1.36
Quarterly revenue growth (yoy)42,711.10%
Gross profit (ttm)N/A
EBITDA -405.8M
Net income avi to common (ttm)-359.36M
Diluted EPS (ttm)-1.480
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)2.72B
Total cash per share (mrq)9.83
Total debt (mrq)477.92M
Total debt/equity (mrq)16.00%
Current ratio (mrq)9.36
Book value per share (mrq)10.80

Cash flow statement

Operating cash flow (ttm)-303.62M
Levered free cash flow (ttm)-721.97M